$6.86
+1.3%Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
SGMT • NASDAQ
| Sagimet Biosciences Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
35M | 75.8M | 75.1M | 158K | 56.7M | 68.7M | 10.2M | |
78.1M | 75.4M | 19.8M | 32.2M | 0.0 | 0.0 | 0.0 | |
113.1M | 151.3M | 94.9M | 32.3M | 56.7M | 68.7M | 10.2M | |
0.0 | 1.1M | 1.4M | 413K | 423K | 0.0 | 545K | |
3.3M | 463K | 397K | 34K | 1.5M | 36K | 58K | |
116.4M | 152.8M | 96.6M | 32.8M | 58.7M | 68.7M | 10.8M | |
NON-CURRENT ASSETS | |||||||
78K | 77K | 73K | 212K | 342K | 194K | 318K | |
0.0 | 7.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 27K | 27K | 27K | 27K | |
78K | 7.5M | 73K | 239K | 369K | 221K | 345K | |
116.5M | 160.3M | 96.7M | 33M | 59M | 69M | 11.2M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
1.3M | 1.4M | 186K | 1.1M | 761K | 513K | 1.2M | |
1.3M | 1.4M | 186K | 1.1M | 761K | 513K | 1.2M | |
0.0 | 2.9M | 4.8M | 4M | 1.4M | 1M | 747K | |
78K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 78K | 65K | 133K | 124K | 145K | 130K | |
3.7M | 5K | 556K | 57K | 185K | 243K | 0.0 | |
5.1M | 4.5M | 5.7M | 5.3M | 2.4M | 1.9M | 2.1M | |
NON-CURRENT LIABILITIES | |||||||
0.0 | 0.0 | 0.0 | 214.6M | 214.6M | 202.9M | 134.2M | |
0.0 | 0.0 | 0.0 | 214.7M | 214.9M | 203M | 134.4M | |
0.0 | 78K | 65K | 211K | 348K | 210K | 341K | |
5.1M | 4.5M | 5.7M | 220M | 217.3M | 204.9M | 136.5M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 134.2M | |
3K | 3K | 2K | 1K | 1K | 1K | 1K | |
457.6M | 450.9M | 340.8M | 35M | 33.1M | 31M | 30.2M | |
-346.3M | -295.3M | -249.7M | -221.9M | -191.4M | -166.9M | -155.6M | |
120K | 230K | 30K | -84K | 0.0 | 0.0 | 0.0 | |
111.4M | 155.8M | 91.1M | -187M | -158.3M | -135.9M | -125.3M | |
111.4M | 155.8M | 91.1M | -187M | -158.3M | -135.9M | -125.3M | |
SUMMARY | |||||||
116.5M | 160.3M | 96.7M | 33M | 59M | 69M | 11.2M | |
78.1M | 82.8M | 19.8M | 32.2M | 0.0 | 0.0 | 0.0 | |
78K | 78K | 65K | 211K | 348K | 210K | 341K | |
-34.9M | -75.8M | -75.1M | 53K | -56.4M | -68.5M | -9.9M | |
31,001,109 | 31,001,109 | 31,001,109 | 31,001,109 | 31,001,109 | 31,001,109 | 31,001,109 |
SGMT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 20, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | June 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 11, 2026 | March 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 11, 2026 | December 31, 2025 | 2025 |
Continue your SGMT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.